Texas NeuroAIDS Research Center

摘要 这项申请是为了补充过渡性资金，以维持德克萨斯州神经艾滋病中心的运营 研究中心(TNRC)的一段时间(U24MH10093010)。该项目招募艾滋病毒阳性者 病人在医学和神经心理学上具有特征，在以下情况下进行尸检 适当的，维护一个人类标本储存库，并在世界各地分发标本。这个 该合作协议U24第5财年的资金将于2023年2月28日结束。从现在起 编写该程序是在一个免费扩展上操作的，该扩展结合了一个挂起的“进位”请求 结转“前几年尚未核准的资金。继续拨款的申请 VIA合同正在接受美国国家卫生研究院的审查。根据联邦官员的说法，关于资金的决定 未来的情况将在U24结束后大约六个月内不得而知。它已经创造了 “资金缺口”。根据联邦官员的建议，我们正在申请补充桥梁 在国家卫生研究院发布关于长期资金的决定之前，为维持正常运作提供资金。我们 我们被建议申请到2023年8月31日之前允许运营的资金，这相当于 从U24结束时起，大约六个月的正常运行。我们要求过渡性资金 按照美国国立卫生研究院建议的方式计算。我们已经从我们的请求中扣除了 潜在可用资金的两个来源：1)可用于核准的无成本的余额 延期，以及2)与待决的未支出结转请求相对应的单独金额 前几年的资金。假设这两项请求都得到了美国国立卫生研究院的批准和颁布， 我们计算了运营到2023年9月1日所需的额外资金。那 数额反映在我们的预算请求及其理由中。请求补充资金，以 维持运营，直到项目资金的长期计划变得明确为止。

Abstract This application is for supplemental bridge funding to maintain operation of the Texas NeuroAIDS Research Center (TNRC) for a brief period of time (U24MH10093010). This project recruits HIV positive patients, characterizes them medically and neuropsychologically, performs autopsies when appropriate, maintains a human specimen repository, and distributes specimens worldwide. The funding for fiscal year 5 of this cooperative agreement U24 was to end on February 28, 2023. As of this writing the program is operating on a no cost extension combined with a pending request for “carry forward” funds from prior years that has not yet been approved. The application for continued funding via contracting is under a review by the NIH. According to federal officials the decision regarding funding in the future will not be known for approximately six months from the end of the U24. That has created a “funding gap.” Following the advice of federal officials, we are applying for supplemental bridge funding to maintain normal operations until a decision on long term funds is issued by the NIH. We were advised to apply for funds that will allow operation through August 31, 2023, which amounts to roughly six months of normal operation from the time the U24 was to end. Our request for bridge funds for that period is calculated in a manner suggested by the NIH. We have subtracted from our request two sources of potentially available funds: 1) the balance that was available for an approved no cost extension, and 2) a separate amount corresponding to a pending request for carry forward of unspent funds from prior years. Assuming that these two requests are both approved and enacted by the NIH, we calculated an amount of additional funds necessary to operate through September 1, 2023. That amount is reflected in our budget request and its justification. Supplemental funding is requested to maintain operation until the long-term plan for funding the project become clear.